Biomedical Materials Translational Facility
Biomedical Materials Translational Facility (BMTF) in the Clayton Manufacturing and Materials Sciences Precinct
The Biomedical Materials Translational Facility will be led by Monash University and CSIRO based at their joint Clayton precinct in Melbourne with partners MIMR-PHI and ANSTO.
The SIEF investment has leveraged $10 million respectively from CSIRO and Monash, and the rest invested from emerging industry partners, and has a particular focus on the ‘3D’s’ – materials and IP for delivery, diagnostics and devices – applied to the diagnosis and treatment of key chronic diseases – cardiovascular, cancer and ophthalmic diseases.
The Clayton precinct is developing as a manufacturing centre for the future and area of strength for Australia. “This is a major collaborative effort between CSIRO, Monash and 20 emerging industry players and will build on Australia’s global competitiveness,” former CSIRO Chief Executive and Science and Industry Endowment Fund Trustee Dr Megan Clark said at the launch.
“The innovation led by this facility will foster rapid progress in materials and biomedical sciences and assist in commercialising the next generation of medical devices, diagnostics and cell therapies,” said Monash University’s Professor Ian Smith, Vice-Provost (Research and Research Infrastructure).
The BMTF aims to provide three synergistic areas critical to the translation of biomedical materials research:
- Clean room materials synthesis, fabrication and surface coating.
- High throughput biological testing and evaluation of materials.
- Large animal models and real-time non-invasive imaging for pre-clinical studies.
Development of new medtech products, particularly medical devices is technically challenging, and invariably requires a multidisciplinary approach with research expertise drawn from a range of disciplines such as materials science, surface chemistry, biomedical engineering, cellular biology and pre-clinical assessment. The BMTF aims to provide an environment in which the existing research expertise from partners and collaborators will come together to create critical mass in collaborative multidisciplinary research teams, to develop new materials for devices, diagnostics, delivery technologies, imaging agents and the assessment of these materials through new, non-invasive, in situ imaging techniques. The BMTF will allow discoveries to be accelerated through the next phases of scale-up, prototype evaluation and biological testing.
The BMTF will be a focal point to draw in, engage and stimulate industry. Within Australia’s medtech sector there are a range of highly innovative companies with high growth potential. The BMTF’s focus on translational biomedical materials research provides these companies with a means to proactively engage earlier in the R&D process.
- CSIRO News Release
- Ministerial Media Release